Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis

Acute Pancreatitis Clinical Trial

— DIAGNON  

Official title:

Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03634787
• Other study ID #: 158200-17-941-455
• Status: Recruiting
• Start date: October 20, 2017
• Est. completion date: December 30, 2021

Study information

• Verified date: August 2018
• Source: Vilnius University
• Contact: Kestutis Strupas, Prof. MD/PhD
• Phone: +37052365000
• Email: kestutis.strupas[@]santa.lt
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To investigate the role of Heat Shock Proteins in the mechanism of acute severe pancreatitis. In addition to test the potential treatment target of acute pancreatitis.

All patients who present with clinical symptoms of acute pancreatitis are evaluated for the enrollment of the study.

Description:

All patients with acute pancreatitis are evaluated according to modified Atlanta classification acute pancreatitis severity scores.

Blood serum, urine and DNA samples are collected from all patients presented on admission, after 24 hours, 48 hours, 72 hours.

CT is performed in al patients to evaluate necrosis of pancreas Day 5-7 since hospital admission. If necrosis is not present follow-up is stopped.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 280
• Est. completion date: December 30, 2021
• Est. primary completion date: December 2021
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• no prior diagnosis of acute pancreatitis

• admission to the hospital within 2 days since the clinical symptoms

• confirmed diagnosis of acute pancreatitis

Exclusion Criteria:

• chronic pancreatitis

• pancreatic cancer

Related Conditions & MeSH terms

• Acute Pancreatitis
• Pancreatitis

Intervention

Diagnostic Test:
• CT Scan Day 5-7
Computed Tomography on Day 5-7 according to a clinical protocol.

Locations

Country	Name	City	State
Lithuania	Vilnius University Hospital "Santaros Klinikos	Vilnius

Sponsors (1)

Lead Sponsor	Collaborator
Vilnius University

Country where clinical trial is conducted

Lithuania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To measure the levels of heat shock proteins in serum and plasma in acute severe pancreatitis settings	Different molecular weight Heat Shock proteins role while developing acute pancreatitis.	2 years
Secondary	To measure pancreas cells activity while applying Heat Shock Protein inhibitors	To establish a mechanism explaining the potential use of heat shock proteins inhibitors/ activators for treatment of acute pancreatitis	2 years